<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <p>Most recently, Bill was the Chief Financial Officer of Aerin
            Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
        <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
            Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
            to
            Artvivion (CryoLife) in 2016. </p>
        <p>Early in his career, Bill spent nine years specializing in
            healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
            followed by
            executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
            and Acxiom
            Corporation. </p>
        <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
            and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
            Committees until
            their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
            numerous other
            boards of directors or advisory boards including public, private, non-profit and private
            equity/venture
            capital.</p>
    </div>
    <span id="profile-name">Bill Mccellan</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class="">Advisor, Distalmotion</p>
                <p class="">CFO, Aerin Medical, Inc. </p>
                <p class="">CFO and Executive VP, On-X Life Technologies (Acquired) </p>
                <p class="">Director, Apollo Endosurgery (Acquired) Director, Reata
                    Pharmaceuticals (Acquired) </p>
                <p class="">Price Waterhouse Coopers (PWC)</p>
            </div>
        </div>
    </div>
</div>



<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <p class="" id="yui_3_17_2_1_1714590605910_161">Diane recently served as Chief Commercial Officer for Better
            Therapeutics, where she focused on the company’s commercial capabilities and led the launch of AspyreRx, an
            FDA-authorized prescription digital therapeutic delivering cognitive behavioral therapy for the treatment of
            Type II Diabetes. </p>
        <p class="">Prior to Better Therapeutics, was the U.S. President of Galderma responsible for integrating its
            aesthetic, consumer care and prescription medicines business units following its divestiture from Nestlé.
        </p>
        <p class="">From 2003 to 2021, Diane spent nearly two decades at Johnson &amp; Johnson in strategic and
            commercial roles in its medtech sector ultimately serving as the Worldwide President of Mentor, a women’s
            surgical breast aesthetics business. </p>
        <p class="">Diane began at J&amp;J as a member of the Cordis team who launched Cypher, the first drug eluting
            stent. At Ethicon, Diane led the Biosurgery franchise and commercialized the Evarrest fibrin sealant patch
            for rapid hemostasis of problematic bleeding in surgery. </p>
        <p class="">Diane serves as an Executive Strategic Advisor to InSoma Biotech, an early-stage start-up developing
            novel injectable material to mimic human tissue. She serves on the Board of Directors for Workforce
            Solutions Dallas, appointed by Dallas Mayor Eric Johnson. Diane also sits on the Board of the Association of
            Latino Princeton Alumni.</p>
    </div>
    <span id="profile-name">DIANE GOMEZ-THINNES</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class="">Chief Commerical Officer, Better Therapeutics </p>
                <p class="">U.S. President, Galderma </p>
                <p class="">WW President, Mentor (J&J) </p>
                <p class="">Strategic Marketing, Cordis & Ethicon (J&J)</p>
            </div>
        </div>
    </div>
</div>


<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">
            <p class="">Glen is currently the CEO of Highridge Medical, previously,
                the spine division of ZimVie. </p>
            <p class="">Prior to Highridge Medical, Glen was the CEO of Cerapedics
                Inc., a privately held Ortho-biologics company focused on developing and commercializing
                peptide-enhanced bone graft products. </p>
            <p class="">Glen has also served as Worldwide President for Spine &amp;
                Bone Healing Technologies, Inc., a division of Biomet Inc. Additionally, Glen concurrently served as
                Senior Vice President on Biomet’s Worldwide Operating Board, encompassing the Orthopedics, Spine,
                Trauma, Biologics, and Sports Medicine businesses. Previously, he has held a number of Divisional
                president roles at Johnson &amp; Johnson where he served as Worldwide President for Cordis
                Endovascular and Neurovascular and as Worldwide President for Codman Neuro Sciences and U.S.
                President of DePuy Spine. </p>
            <p class="">In addition to his corporate roles, Glen has concurrently
                managed a contract manufacturing business, Ortho-Craft that was acquired by Paragon Medical in 2005.
                He has also served several board of director positions including SpineView, Palyon Medical, Veniti
        </div>
    </div>
    <span id="profile-name">Glen Kashuba</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class="">CEO, Highridge Medical </p>
                <p class="">CEO, Cerapedics </p>
                <p class="">WW President, Spine and Bone, Biomet </p>
                <p class="">WW President for Cordis Endovascular and Neurovascular (J&amp;J) </p>
                <p class="" id="yui_3_17_2_1_1714590763257_146">WW President for Codman Neuro (J&amp;J) U.S. President
                    of DePuy Spine (J&amp;J)</p>
            </div>
        </div>
    </div>
</div>


<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">

            <p class="">Glenn Mattes has more than 30 years of healthcare enterprise leadership and executive
                experience. He has served in executive capacities in large pharmaceutical companies, biotech and device
                focused companies in both public and private domains. </p>
            <p class="">Most recently, Glenn was CEO at TFF, Inc., a pharmaceutical company developing a novel
                inhalation therapy technology platform with an IPO in 2023. Glenn has been involved at a number of
                development stage companies as CEO and Board level. </p>
            <p class="">Glenn’s specific company experience includes Johnson &amp; Johnson, Rhône Poulenc Rorer,
                ConvaTec, Candel, Centocor, TFF, Arno Therapeutics, Translational Sciences, The Gores Group, and the
                Clayton Foundation for Research. </p>
            <p class="">Glenn was appointed to the President’s Advisory Committee on HIV/AIDS by President George W.
                Bush and the U.S. Secretary of Health and Human Services.</p>

        </div>
    </div>
    <span id="profile-name">Glen Mattes</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class="">CEO, kaleo (Acquired) </p>
                <p class="">Director, Avenu Meidcal (Acquired) </p>
                <p class="">Vice President, Cardiac Rhythm Management, Boston Scientific</p>
            </div>
        </div>
    </div>
</div>


<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">
            <p class="">Kevin has served as a member of the Board of Directors of Silk Road Medical, a publicly traded
                company focused on reducing the risk of stroke, since December 2020. </p>
            <p class="">From July 2020 to September 2023, Kevin served as President of Aldevron, a privately held
                genomics company that was acquired by Danaher Corporation in August 2021. </p>
            <p class="">Prior to joining Aldevron, Kevin spent 25 years at Boston Scientific Corporation. During his
                last nine years at Boston Scientific, Kevin served as Executive Vice President and Global President of
                the Interventional Cardiology division. Kevin has served on the board of directors of Shockwave Medical,
                Inc., since June 2023.</p>
        </div>
    </div>
    <span id="profile-name">KEVIN BALLINGER</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class="">Director, Silk Road Medical (NASDAQ: SILK) </p>
                <p class="">Director, Shockwave Medical (NASDAQ: SWAV) </p>
                <p class="">President, Aldevron (Acquired) </p>
                <p class="">Executive VP and Global President, Boston Scientific (Interventional Cardiology)</p>
            </div>
        </div>
    </div>
</div>


<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">

            <p class="">Martin spent over 30 years at McKinsey &amp; Company where he led the global life sciences
                practice for 7 years ( 2014-2021) and co-founded/ co-led the McKinsey health institute (a non-profit
                generating initiative focused on extending healthspan). </p>
            <p class="">Martin served clients across medical devices, biopharma and consumer health in North America,
                Europe, Asia and Middle East and South Africa. Earlier in his McKinsey career, he led the cross-industry
                organization practice in EMEA. </p>
            <p class="">In addition to his board role at Distalmotion, Martin is also chair of the advisory board at
                Medgenome.</p>

        </div>
    </div>
    <span id="profile-name">MARTIN DEWHURST</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class="">Director, Distalmotion </p>
                <p class="">Partner / Global Lead Healthcare &. Life Sciences, McKinsey & Company</p>
            </div>
        </div>
    </div>
</div>


<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">

            <p class="">Nadav brings 23 years of global, multi-segment general management
                experience in Medtech. </p>
            <p class="">Nadav is the CEO of Cynosure an energy based aesthetics device
                maker and lead the acquisition and merger with Lutronic announced in January, 2024. </p>
            <p class="">Prior to Cynosure Nadav was with Johnson &amp; Johnson for 22
                years where he last served as Global President, Spine for DePuy Synthes Companies. Additional roles at
                J&amp;J include Vice President, for in the Diabetes Care franchise, including commercial activity for
                LifeScan and Animas subsidiaries as well as Vice President, Sales &amp; Marketing, for the
                cardiovascular franchise including Cordis &amp; Biosense Webster. </p>
            <p class="">Nadav serves as a director for a Revival portfolio company,
                Augmedics, and leads Revival’s Israeli relations and strategy.</p>


        </div>
    </div>
    <span id="profile-name">Nadav Tomer</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class="">CEO, Cynosure (Acquired) </p>
                <p class="">Global President, Depuy Synthes (J&J) </p>
                <p class="">Vice President, J&J (Diabetes Franchise, Cordis & Biosense Webster) </p>
            </div>
        </div>
    </div>
</div>


<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">
            <p class="">Regina Benjamin, MD, MBA is the Founder and CEO of Bayou Clinic,
                and was the 18th United States Surgeon General (2009-2013). </p>
            <p class="">As U.S. Surgeon General, Dr. Benjamin oversaw the operational
                command of 6,500 uniformed public health officers who serve in locations around the world to promote and
                protect the health of the American People. As chair of the National Prevention Council – 17
                cabinet-level Federal Agency Heads, she led the development of the National Prevention Strategy:
                America’s Plan for Better Health and Wellness. </p>
            <p class="">In 1995, she was the first physician under the age of 40 and the
                first African-American woman to be elected to the American Medical Association Board of Trustees. Other
                past board memberships included the Robert Wood Johnson Foundation, Kaiser Family Foundation Commission
                on Medicaid and the Uninsured, Catholic Health Association, and Morehouse School of Medicine. </p>
            <p class="">She currently serves on the boards of Kaiser Hospitals and Health
                Plan; Ascension Health Alliance; ConvaTec PLC; Computer Technology Systems Inc (CPSI); and the American
                Heart Association. </p>
            <p class="">Dr. Benjamin is a member of the Institute of Medicine and a Fellow
                of the American Academy of Family Physicians. </p>
            <p class="">In 1998 Dr. Benjamin was the United States recipient of the Nelson
                Mandela Award for Health and Human Rights. She received the 2000 National Caring Award, which was
                inspired by Mother Teresa and was recognized with the Papal honor Pro Ecclesia et Ponticifice from Pope
                Benedict XVI. In 2008, she was honored with a MacArthur Genius Award Fellowship. In 2011, Dr. Benjamin
                became the recipient of the Chairman’s Award at the 42nd NAACP Image Awards. In May 2013, Reader’s
                Digest, ranked her #22 of the “100 Most Trusted People in America”.</p>
        </div>
    </div>
    <span id="profile-name">Regina Benjamin, MD</span>
    <div id="profile-mini">
        <<div class="image-subtitle sqs-dynamic-text" data-width-percentage="44" style="font-size: max(0.75rem, 44%);"
            id="yui_3_17_2_1_1714591257638_147">
            <p class="" id="yui_3_17_2_1_1714591257638_146">18th United States Surgeon
                General (2009-2013) Director</p>
            <p class="">Kaiser Hospitals and Health Plan Director</p>
            <p class="">Ascension Health Alliance Director</p>
            <p class="">ConvaTec PLC Director, American Heart Association Founder and CEO
                of BayouClinic</p>
    </div>
</div>
</div>
</div>


<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">


            <p class="">Sholmi has over 25 years of experience in the medical device
                industry and is currently serving as board member on multiple companies in the medical device industry
                as well as a board member at the Arnold and Mable Beckman Foundation, a foundation focused on supporting
                research in chemistry and life sciences.</p>
            <p class="">Previously, Shlomi held senior operating roles at Johnson &amp;
                Johnson, where he was the Company Group Chairman of Cardiovascular and Specialty Solutions and Visions
                Group within the Medical Devices sector. He was a member of the Medical Devices Group Operating
                Committee and lead a diverse portfolio of 6 diverse medical device businesses including
                Electrophysiology, Neurovascular Intervention, Ear, Nose &amp; Throat, Breast Aesthetics, Optometry and
                Ophthalmology. Prior to that, Nachman had various roles with increase scope and responsibilities
                including Worldwide President of Biosense Webster and Cordis.</p>

        </div>
    </div>
    <span id="profile-name">SHLOMI NACHMAN</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class=""><em>Company Group Chairman of Cardiovascular and Specialty
                        Solutions (J&amp;J) </em></p>
                <p class=""><em>Company Group Chairman of Visions Group (J&amp;J) </em>
                </p>
                <p class=""><em>Worldwide President of Biosense Webster and Cordis
                        (J&amp;J)</em></p>
            </div>
        </div>
    </div>
</div>


<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">


            <p class="">Yann co-founded and lead Cardiologs as the CEO from its formation in 2014 until 2021 when it was
                acquired by Phillips. Yann remained with Phillips as the General Manager until December 2022. </p>
            <p class="">Cardiologs was a France-based SaSS cardiovascular diagnostics SaSS company that utilized
                artificial intelligence (AI), deep learning and cloud technology at a global scale to aid in the
                analysis of electrocardiograms (ECG’s) and obtained regulatory clearances – both CE Mark in 2016 from
                the FDA in 2017.</p>

        </div>
    </div>
    <span id="profile-name">YANN FLEUREAU</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class="">Co-Founder and CEO, Cardiologs </p>
                <p class="">General Manager, Phillips</p>
            </div>
        </div>
    </div>
</div>



<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">


            <p class="">Tiffanie has spent the last 13 years as the Managing Principal of her own consulting company
                where she leverages her broad experiences to assist multinational, early-stage startups, and large
                Fortune 500 companies plan and execute strategies for clinical research and evidence generation, as well
                as for regulatory, product development, commercial, and market access &amp; reimbursement. </p>
            <p class="">Additionally, Tiffanie serves as a facilitator, coach, and judge for the Value Workshop program
                for MedTech Innovator Accelerator and Venture, a nonprofit, global competition and accelerator for
                medical device, digital health, and diagnostic companies. </p>
            <p class="">Previously, Tiffanie was the Vice President of Clinical &amp; Medical Affairs at Apollo
                Endosurgery, where as a part of the executive team, she lead all Global Clinical and Medical Affairs
                activities, including regulated studies and strategic planning of all global reimbursement processes
                with a focus on securing FDA approval for key products. </p>
            <p class="">Earlier roles for Tiffanie included, Director of Global Market Development with Covidien,
                Marketing Manager with Stryker Corporation, as well as Senior Product Manager and Product Manager with
                Stryker Corporation.</p>

        </div>
    </div>
    <span id="profile-name">TIFFANIE GILBRETH</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class="">Vice President of Clinical & Medical Affairs at Apollo Endosurgery </p>
                <p class="">Director Market Development, Covidien</p>
            </div>
        </div>
    </div>
</div>


<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">



            <p class="">Victor (Vic) Chance is the President of BVC Consulting which provides consulting services in
                productivity improvement, operations excellence, supply chain strategies, strategic procurement and
                execution support for the supply chain and procurement functions. </p>
            <p class="">Previously Vic served as Vice President, External Operations and Supply Chain Chief Procurement
                Officer for the Medical Device &amp; Diagnostics Sector of Johnson &amp; Johnson. In those roles, Vic
                was responsible for the external supplier network along with all associated external supply performance
                improvement. </p>
            <p class="">In addition, Vic was also World-wide Vice President of Operations at Cordis and Ortho-Clinical
                Diagnostics – both Johnson and Johnson subsidiaries at the time. While Vic was at Cordis, they received
                recognition for operations excellence by receiving the Shingo Prize for Manufacturing as well as being a
                two-time winner of Industry Week’s “America’s Best Plants” award (Juarez, MX and San German, PR).</p>

        </div>
    </div>
    <span id="profile-name">VICTOR CHANCE</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class="">Operations Advisor, Distalmotion</p>
                <p class="">CPO, J&J Medical Devices and Diagnostics</p>
                <p class="">VP, External Operattions J&J </p>
                <p class="">WW VP, Operations, Cordis and Ortho-Clinical Diagnostics (J&J)</p>
            </div>
        </div>
    </div>
</div>


<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">



            <p class="">Spencer was CEO and board member of Kaleo, Inc from 2016 to 2021. While at Kaleo, Spencer led
                the growth of the company from a three-person start-up to a business with five FDA approved drug-device
                combination products. In 2021 Kaleo was acquired by Marathon Asset Management for $310M, including
                milestones. </p>
            <p class="">Spencer has also on the board of Avenu Medical which developed a percutaneous AV fistula
                catheter product for chronic kidney disease patients. Avenu was acquired in 2020 by Medtronic. </p>
            <p class="">Before Spencer’s private company experience, he held senior executive level positions with
                Guidant / Boston Scientific in the Cardiac Rhythm Management division.</p>

        </div>
    </div>
    <span id="profile-name">SPENCER WILLIAMSON</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class="">CEO, kaleo (Acquired) </p>
                <p class="">Director, Avenu Meidcal (Acquired) </p>
                <p class="">Vice President, Cardiac Rhythm Management, Boston Scientific</p>
            </div>
        </div>
    </div>
</div>


<a id="bio-link"></a>
<div id="data-source" style="display: none">
    <div id="long-bio">
        <div class="sqs-block-content">



            <p class="">As the the Chief Growth Officer at Commure, Manisha was
                responsible for sales, marketing, customer success, operations, and partnerships organizations. </p>
            <p class="">Before joining Commure, Manisha held leadership positions in the
                intersection of healthcare and technology serving as the Chief Operating Officer at Clarify Health
                Solutions, a technology company focused on analytical software solutions for payers, providers, and life
                sciences customers. </p>
            <p class="">Prior to Manisha’s operating roles, she was a Partner at McKinsey
                &amp; Company in the medical products, life sciences, and health systems/payor practices in the US, UK,
                and emerging markets. Her focus at McKinsey for over a decade was commercial growth and innovation with
                impact, including the use of technology and data to drive outcomes at improved cost for the health
                ecosystem. </p>
            <p class="">Prior to McKinsey Manisha worked in global health and healthcare
                investing at Acumen, the UNDP in Ethiopia, and the American India Foundation. </p>
            <p class="">Manisha currently serves as a member of the Board of Directors for
                Model N, a public company that focuses on revenue lifecycle management software for life sciences
                companies, and as Chair of the Board of Directors at ReSurge International, a nonprofit humanitarian aid
                organization providing reconstructive surgical care in low-income countries worldwide.</p>


        </div>
    </div>
    <span id="profile-name">MANISHA SHETTY GULATI</span>
    <div id="profile-mini">
        <div class="image-subtitle-wrapper">
            <div class="image-subtitle sqs-dynamic-text">
                <p class=""><strong>Strategic Advisor, Distalmotion</strong></p>
                <p class="">Chief Growth Officer at Commure </p>
                <p class="">Chief Operating Officer at Clarify Health Solutions </p>
                <p class="">Partner at McKinsey &amp; Company Director, Model N </p>
                <p class="">Director, ReSurge International</p>
            </div>
        </div>
    </div>
</div>